Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Susan Boynton, VP, Global Regulatory Affairs, Shire
Oncologic Drugs Advisory Committee
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Federal Institute for Drugs and Medical Devices | The Farm is a Federal Institute within the portfolio of the Federal Ministry of Health (Germany) How.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA.
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
ICTW, Cordoba, Argentina Clinical Research Design & Methodology: Phase III Trials Ian Tannock, MD, PhD, DSc Princess Margaret Cancer Centre & University.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Selected Issues in Oncology Trial Design Grant Williams, M.D. DODP, CDER, FDA.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.
Trastuzumab [Genentech Inc.] Labeling Supplement to Include FISH Testing as a Method to Select Patients for Treatment FDA Clinical Review December 5, 2001.
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.
Drug Treatment of Metastatic Breast Cancer
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
CD-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Martine George, MD Vice President, Therapeutic Area Head Hematology and Oncology.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.
Effective Presentation of Study Results How are RCTs presented in abstracts & publications? and Some things to consider in your own presentations NCIC.
NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
NSABP C08 adjuvant colon cancer Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation)
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Surrogate Endpoints: The Challenges are Greater than they Seem March 7, 2005 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of.
How should efficacy of new adjuvant therapies be evaluated in colorectal cancer? Marc Buyse, ScD IDDI, Brussels, Belgium Based on Daniel Sargent’s talks.
Some Design Issues in Microbicide Trials August 20, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington FDA Antiviral.
Endpoints for Past Approvals Ramzi Dagher DODP/CDER/FDA.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
NSABP Overall Survival and Updated Disease-Free Survival Results of the NSABP C-08 Trial Assessing Bevacizumab in Stage II & III Colon Cancer CJ Allegra,
 Treats a population of < 200,000 in the US  Same review and development standards as for a non- orphan product  Numbers of patients in clinical trials.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.
Endpoints for Pediatric Brain Tumors December 6, 2006 meeting of the Pediatric Subcommittee to ODAC Karen D. Weiss, M.D. Deputy Director Office of Oncology.
Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
CS-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Peter Bowers, MD Senior Director Clinical Team Leader Johnson & Johnson Pharmaceutical.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
Surrogate Endpoints as Measures of Efficacy: Complexities & Limitations FDA Advisory Committee November 18, 2002 Michael D. Hughes, Ph.D. Professor of.
Response, PFS or OS – what is the best endpoint in advanced colorectal cancer? Marc Buyse IDDI, Louvain-la-Neuve & Hasselt University
Defining Success in Oncology Drug Development Richard Pazdur, MD CDER, FDA The views expressed are the results of independent work and do not necessarily.
Statistics in Drug Regulation: The Next 10 Years Thomas Permutt Director, Division of Biometrics II Center for Drug Evaluation and Research The views expressed.
Patient Focused Drug Development An FDA Perspective
Critical Reading of Clinical Study Results
Clinical Trials in STS Shreyaskumar Patel, M.D.
Regulatory perspective
Dr Jessica Jenkins Consultant Oncologist
Jonathan W. Friedberg M.D., M.M.Sc.
Biomarkers as Endpoints
Aimery de Gramont Association between 3 year Disease Free Survival and Overall Survival delayed with improved survival after recurrence in patients receiving.
Presentation transcript:

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA

FDA Colorectal Cancer Workshop (11/12/03) Purpose Purpose –Discussion of positive and negative aspects of various endpoints for approval of new drugs for colorectal cancer –Identify areas for further research –Provide information to ODAC for recommendations to FDA

Colorectal Endpoints Workshop Format Regulatory background and summary of previous approvals provided by FDA Regulatory background and summary of previous approvals provided by FDA Five presentations Five presentations Interactive discussion by speakers and multidisciplinary panel Interactive discussion by speakers and multidisciplinary panel Discussion of questions posed by FDA Discussion of questions posed by FDA

Goals of This Presentation Capsule summary of presentations and main points of discussion Capsule summary of presentations and main points of discussion Focus on possible new endpoints for regulatory approval of drugs for colorectal cancer Focus on possible new endpoints for regulatory approval of drugs for colorectal cancer Help ODAC advise FDA Help ODAC advise FDA

Biomarkers or QOL in CRC Drug Approvals (Dr. Charles Blanke) Not possible to consistently predict clinical benefit based on reduction of CEA Not possible to consistently predict clinical benefit based on reduction of CEA ASCO guidelines do not recommend other biomarkers for CRC ASCO guidelines do not recommend other biomarkers for CRC

Biomarkers or QOL in CRC Drug Approvals (Dr. Charles Blanke) Methodologic issues of paramount importance if QOL used as endpoint Methodologic issues of paramount importance if QOL used as endpoint Unknown whether changes in QOL reliably occur with effective chemo Unknown whether changes in QOL reliably occur with effective chemo Cannot discriminate between safety and efficacy Cannot discriminate between safety and efficacy Best use of resources in colon cancer? Best use of resources in colon cancer?

Biomarkers or QOL in CRC Drug Approvals (Dr. Charles Blanke) Clinical Benefit Response (Pain, performance status, weight loss) Clinical Benefit Response (Pain, performance status, weight loss) CBR does not adequately encompass symptoms experienced by patients CBR does not adequately encompass symptoms experienced by patients Methodologic issues in assessment Methodologic issues in assessment Not useful if asymptomatic (colon vs rectum) Not useful if asymptomatic (colon vs rectum)

Endpoints in Neoadjuvant and Adjuvant Rectal Cancer (Dr. Meg Mooney) Locoregional failures are usually symptomatic in rectal cancer Locoregional failures are usually symptomatic in rectal cancer “Local tumor control at 3 years is an appropriate endpoint for full approval” “Local tumor control at 3 years is an appropriate endpoint for full approval” Pathologic complete response (pCR) - quality control issues Pathologic complete response (pCR) - quality control issues Colostomy-free survival – applies mainly to low lying tumors Colostomy-free survival – applies mainly to low lying tumors

Surrogate Endpoints and Non-Inferiority Trials (Dr. Thomas Fleming) Primary endpoints: sensitive, measurable, and clinically relevant (eg. Survival; decreased symptoms) Primary endpoints: sensitive, measurable, and clinically relevant (eg. Survival; decreased symptoms) Surrogate endpoints Surrogate endpoints –May reflect biological activity without establishing clinical efficacy –Meta-analyses required to validate –Validated surrogate endpoints are rare –FDA has granted approval using surrogate endpoints not formally validated

Surrogate Endpoints and Non-Inferiority Trials (Dr. Thomas Fleming) Non-inferiority trials Non-inferiority trials –Insufficient for curves to overlap –Conservative margins to exclude significant decrease in efficacy –Rigorous study conduct to avoid incorrect conclusion of non- inferiority –Will results move the field forward (eg significant decrease in toxicity)?

TTP: Clinical Benefit Endpoint in 1 st Line MCRC (Dr. Langdon Miller) Multiple effective therapies for metastatic colorectal cancer have confounded the relationship between early tumor control and survival Multiple effective therapies for metastatic colorectal cancer have confounded the relationship between early tumor control and survival Evaluation of symptoms problematic as endpoint because progression frequently not symptomatic, is subjective, and difficult to measure Evaluation of symptoms problematic as endpoint because progression frequently not symptomatic, is subjective, and difficult to measure

TTP: Clinical Benefit Endpoint in 1 st Line MCRC (Dr. Langdon Miller) Arguments for TTP as endpoint for full approval Arguments for TTP as endpoint for full approval –Directly evaluates changes in disease burden –Correlates with other outcomes (in particular, survival) –Not confounded by subsequent therapies –Offers utility as an endpoint in non- inferiority trials (more rapid completion)

TTP: Clinical Benefit Endpoint in 1 st Line MCRC (Dr. Langdon Miller) –Can be objectively quantified, reviewed, and audited –Offers clear interpretation and straightforward analysis –Conserves patient resources and hastens drug development

TTP: Clinical Benefit Endpoint in 1 st Line MCRC (Dr. Langdon Miller) Correlation of TTP and Survival Was Highly Significant: two examples patients in two phase III trials with primary patient data 1.Meta-analysis on published summary results of 29 trials involving 13,000 patients

TTP: Clinical Benefit Endpoint in 1 st Line MCRC (Questions and Comments) 1.Need for objective and reliable methodology for assessing TTP 2.Does TTP reflect clinical benefit in its own right? (Full approval) 3.Is TTP reasonably likely to predict clinical benefit? (Accelerated approval) 4.RR, survival and toxicity also important

3-YR DFS as Endpoint in Adjuvant Colon Cancer (Dr. Dan Sargent) Preliminary findings of meta- analysis to determine if 3-YR DFS can replace 5-YR OS as endpoint for colon cancer adjuvant trials Preliminary findings of meta- analysis to determine if 3-YR DFS can replace 5-YR OS as endpoint for colon cancer adjuvant trials –12 clinical trials –38 treatment arms –> 10,000 patients

3-YR DFS as Endpoint in Adjuvant Colon Cancer (Dr. Dan Sargent) Preliminary Conclusions 1. 3-YR DFS seems to be an excellent predictor of 5-YR OS 2. Event rates were virtually identical (no impact on sample size) 3. 3-YR DFS may slightly overestimate differences in 5-YR OS 4. Three studies – significant difference in 3- YR DFS (borderline p values) but no significant difference in 5-YR OS 5. Not a formally validated surrogate

3-YR DFS as Endpoint in Adjuvant Colon Cancer (Questions and Comments) 1.Work in progress – updated analysis today! 2.Does improvement in 3-YR DFS represent clinical benefit in its own right? 3.DFS is used for full approval in breast cancer adjuvant therapy

Key Questions for ODAC 1. Should the following endpoints be recommended to FDA for new drugs in colorectal cancer? 2. Full or Accelerated approval? Setting Endpoint Setting Endpoint Colon adjuvant 3-YR DFS 1 st line metastatic TTP Rectal adjuvant 3-YR local control